Furthermore, a previous study found that a risk model composed of PTGDR, PNOC and CCL23 was helpful in predicting the prognosis of HER2-positive breast cancer, and that patients with low risk scores may benefit from immunotherapy (68). This evidence concerns the gene PTGDR and breast cancer.